Lenalidomide + CC-486 + Radiation for Plasmacytoma
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing a combination of two drugs and radiation therapy to treat patients with plasmacytoma. The drugs help stop cancer growth and boost the immune system, while radiation kills the cancer cells.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but it does mention that you cannot participate if you are on tacrolimus therapy or concurrent systemic chemotherapy with drugs other than CC-486 and lenalidomide. It's best to discuss your current medications with the trial team to see if they are compatible with the study.
Is the combination of Lenalidomide, CC-486, and Radiation generally safe for humans?
The research articles discuss a condition called radiation recall dermatitis, which is an inflammatory skin reaction that can occur after radiation therapy when certain drugs are administered. This condition is rare and can be managed with treatments like antihistamines and topical steroids, but it highlights a potential safety concern when combining radiation with certain medications.12345
What makes the treatment of Lenalidomide + CC-486 + Radiation unique for plasmacytoma?
This treatment combines lenalidomide, which boosts the immune system's response to cancer, with CC-486 and radiation therapy to target plasmacytoma, a condition with limited standard treatment options. The combination aims to enhance the effectiveness of radiation therapy, which is the most effective for local control of plasmacytoma, by using lenalidomide's ability to improve immune function.678910
What data supports the effectiveness of the drug Lenalidomide in treating plasmacytoma?
Research shows that Lenalidomide, when used with radiation therapy, has been effective in treating solitary plasmacytoma, a type of cancer. Additionally, Lenalidomide has demonstrated anti-tumor activity in various cancers, including multiple myeloma, by enhancing the body's immune response to fight cancer cells.69111213
Who Is on the Research Team?
Urvi Shah, MD
Principal Investigator
Memorial Sloan Kettering Cancer Center
Are You a Good Fit for This Trial?
This trial is for adults with plasmacytoma or multiple myeloma who can take daily aspirin, swallow pills, and have a life expectancy over 3 months. Women must avoid pregnancy and men must not donate sperm during the study. Participants need functioning liver and kidneys, an ECOG status of 0-1, and meet specific blood criteria.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive CC-486 with lenalidomide and radiation therapy for plasmacytoma
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- CC-486
- Lenalidomide
- Radiation Therapy
Find a Clinic Near You
Who Is Running the Clinical Trial?
Memorial Sloan Kettering Cancer Center
Lead Sponsor